ArticleBMC public health2026
Population-based epidemiological study of cervical cancer in Khuzestan province, Iran (2014-2019).
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the third most common cancer and the fourth leading cause of deaths among women worldwide and presents a significant public health challenge, with regional variations in its impact. Understanding the epidemiology of cancer is crucial for policymakers to develop effective prevention strategies. The study provides a comprehensive analysis of the epidemiology of cervical cancer in Khuzestan province, Iran from 2014 to 2019, using data from cancer registries. MATERIALS AND
methodsThis retrospective study reviewed all registered cervical cancer patients in the Khuzestan province over a six-year period 2014–2019. descriptive statistics, Kaplan–Meier survival analysis, and Cox regression was used to assess the impact of demographic characteristics on patient survival, in addition, Age-standardized incidence rates were reported annually. Time series analysis was performed using Minitab to examine temporal disease trends, with the best-fitting model.
resultsA total of 459 cervical cancer cases were analyzed, with a mean age of 54 (SD = 13.02) years. Among these, 91.1% were diagnosed by pathological reports, 5.2% clinically, and 2.6% through death certificates. The highest incidence rate was 2.83 per 100,000 women in 2018, and the lowest was 0.74 in 2014. The five-year survival rate for the studied cases was 65.7%.
conclusionThe incidence of cervical cancer in Khuzestan province increased during 2014–2019, although it declined compared with earlier years. Despite improvements, the five-year survival rate remains lower than other provinces. Persistent challenges include inequities in access to screening and limited availability of HPV vaccination at effective ages. Expanding screening programs, promoting early detection, and improving access to vaccination should be prioritized to reduce the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.